益胃汤合麦门冬汤对脾胃虚弱型胃痞(慢性胃炎)临床预后及肠道菌群的影响OA
Effects of Yiwei Decoction(益胃汤)and Maimendong Decoction(麦门冬汤)on Clinical Prognosis and Intestinal Flora of Patients with Stomach Stuffiness of Spleen-Stomach Weakness Type(Chronic Gastritis)
目的 探究益胃汤合麦门冬汤对脾胃虚弱型胃痞患者临床预后及肠道菌群的影响.方法 选取脾胃虚弱型胃痞患者116例,随机分为对照组及观察组,每组58例.对照组给予四联疗法,观察组在对照组的基础上加用益胃汤合麦门冬汤,疗程4周.分别于治疗前后比较两组患者临床疗效、中医证候评分、血清指标、胃肠激素、幽门螺杆菌(helico-bacter pylori,Hp)转阴情况及肠道菌群.结果 治疗后,观察组总有效率为94.83%(55/58),显著优于对照组(79.31%,46/58)(P<0.05),观察组Hp清除率为96.55%(56/58),对照组Hp清除率为86.21%(50/58);两组患者中医证候评分均显著降低(P<0.05),观察组评分显著低于对照组(P<0.05);两组患者白细胞介素-6(interleukin-6,IL-6)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、C 反应蛋白(C-reactive protein,CRP)均较治疗前显著降低(P<0.05),观察组显著低于对照组(P<0.05);两组患者生长抑素(somatostatin,SS)及表皮生长因子(epidermal growth factor,EGF)均显著升高(P<0.05),且观察组显著高于对照组(P<0.05);两组患者胃泌素(gastrin,GAS)显著降低,且观察组显著低于对照组(P<0.05);两组患者双歧杆菌、乳杆菌较治疗前增加(P<0.05),观察组显著高于对照组(P<0.05);两组患者葡萄球菌及肠球菌较治疗前减少(P<0.05),观察组显著低于对照组(P<0.05).结论 益胃汤合麦门冬汤对脾胃虚弱型胃痞患者临床疗效显著,可改善临床症状,减轻炎症反应,改善患者肠道菌群.
Objective To investigate the effects of Yiwei Decoction(益胃汤)and Maimendong Decoction(麦门冬汤)on the clinical prognosis and intestinal flora of patients with stomach stuffiness of spleen-stomach weakness type.Methods A total of 116 patients with stomach stuffiness of spleen-stomach weakness type were selected and randomly divided into control group and observation group,58 cases in each group.The control group was given quadruple therapy,and the observation group was treated with Yiwei Decoction and Maimendong Decoction on the basis of the control group for 4 weeks.Before and after the treatment,the two groups were compared in terms of clinical efficacy,traditional Chinese medicine symptom scores,serum indexes,gastrointesti-nal hormones,Helicobacter pylori(Hp)conversion and intestinal flora.Results After treatment,the total effective rate of the ob-servation group was 94.83%(55/58),which was significantly better than that(79.31%,46/58)of the control group(P<0.05),and the Hp clearance rate of the observation group was 96.55%(56/58),while that the control group was 86.21%(50/58).The traditional Chinese medicine symptom scores of the patients in both groups were significantly reduced(P<0.05),and the scores of the observation group were significantly lower than those of the control group(P<0.05).The levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),transforming growth factor-β1(TGF-β1)and C-reactive protein(CRP)of two groups were significantly lower than those before treatment(P<0.05),and the levels of the observation group were signifi-cantly lower than those of the control group(P<0.05).The levels of somatostatin(SS)and epidermal growth factor(EGF)were significantly higher in both groups(P<0.05),and the levels of the observation group were significantly higher than those of the control group(P<0.05).the level of gastrin(GAS)was significantly lower in both groups,and the level of the observation group was significantly lower than that of the control group(P<0.05).Bifidobacterium and Lactobacillus increased in both groups compared with those in the pre-treatment period(P<0.05),and Bifidobacterium and Lactobacillus of the observation group were significantly higher than those of the control group(P<0.05).Staphylococcus and Enterococcus decreased in both groups compared with those in the pre-treatment period(P<0.05),and Staphylococcus and Enterococcus of the observation group were significantly lower than those of the control group(P<0.05).Conclusion The clinical efficacy of Yiwei Decoction combined with Maimendong Decoction on patients with stomach stuffiness of spleen-stomach weakness type is remarkable,which can improve the clinical symptoms,reduce the inflammatory reaction and improve the intestinal flora of patients.
刘高仁;张欣;王迎春;张勤生
河南中医药大学第二附属医院,河南郑州 450002河南中医药大学第二附属医院,河南郑州 450002河南中医药大学第二附属医院,河南郑州 450002河南中医药大学第二附属医院,河南郑州 450002
医药卫生
益胃汤麦门冬汤脾胃虚弱型胃痞肠道菌群
Yiwei Decoction(益胃汤)Maimendong Decoction(麦门冬汤)spleen-stomach weakness typestomach stuff-inessintestinal flora
《中华中医药学刊》 2026 (1)
34-37,4
国家中医药管理局中医药循证能力提升项目(2019XZZX-XH005)河南省卫生健康委员会国家中医临床研究基地科研专项(2021JDZX2058)
评论